omniture
Innovent Biologics,Inc

Latest News

Clinical Trial Results of the BCMA CAR-T Co-developed by Innovent and IASO Biotherapeutics Commented in American Society of Hematology's Medical Journal "Blood"

SAN FRANCISCO, U.S. and SUZHOU, China, June 3, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Inno...

2021-06-03 08:00 3128

Innovent Biologics and AnHeart Therapeutics Jointly Announce Exclusive License Agreement for Taletrectinib in Greater China

SAN FRANCISCO and SUZHOU, China, June 1, 2021 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (...

2021-06-01 08:00 2532

Innovent Announces First Patient Dosed in China in the Global Phase 3 Clinical Trial of Pemigatinib as the First-line Treatment of Unresectable or Metastatic Cholangiocarcinoma

SAN FRANCISCO and SUZHOU, China, May 25, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent")...

2021-05-25 08:00 9766

Innovent Will Publish Multiple Clinical Data at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting

SAN FRANCISCO and SUZHOU, China, May 17, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent")...

2021-05-17 09:00 2316

Innovent and Lilly Release Phase 3 Results of TYVYT® (Sintilimab Injection) as a Second-Line Treatment for Squamous Non-Small Cell Lung Cancer at AACR Annual Meeting 2021

SAN FRANCISCO and SUZHOU, China, April 13, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent...

2021-04-13 08:00 2472

Innovent Announces Parsaclisib (IBI376) was Granted Breakthrough Therapy Designation by the NMPA for the Treatment of Relapsed/Refractory Follicular Lymphoma

SAN FRANCISCO and SUZHOU, China, March 31, 2021 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent)...

2021-03-31 08:00 2366

Innovent Announced Financial Results for Full Year Ended December 31, 2020 and Corporate Progress

SAN FRANCISCO and SUZHOU, China, March 30, 2021 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent)...

2021-03-30 20:52 1942

Innovent Announces First Patient Outside China Dosed in the Phase 1 Clinical Trial of Anti-CD47/PD-L1 Bispecific Antibody

SAN FRANCISCO and SUZHOU, China, March 1, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent"...

2021-03-01 08:23 4405

The BCMA CAR-T Co-developed by Innovent and IASO Was Granted Breakthrough Therapy Designation by the NMPA for the Treatment of Relapsed/Refractory Multiple Myeloma

SAN FRANCISCO and SUZHOU, China, Feb. 23, 2021 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) ...

2021-02-23 09:22 3675

Innovent Announces an Out-license Agreement with PT Etana Biotechnologies Indonesia to Launch BYVASDA® (Bevacizumab Biosimilar) in Indonesia

SAN FRANCISCO and SUZHOU, China, Jan. 19, 2021 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) ...

2021-01-19 08:00 4862

Innovent Announces NMPA Acceptance of a Supplemental New Drug Application for Sintilimab as Second-Line Therapy for Squamous Non-Small Cell Lung Cancer

SAN FRANCISCO and SUZHOU, China, Jan. 12, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent"...

2021-01-12 13:02 3997

Innovent Announces the NMPA Granted New Indication Approval for BYVASDA® (Bevacizumab Biosimilar) for the Treatment of Adult Recurrent Glioblastoma

SAN FRANCISCO and SUZHOU, China, Dec. 28, 2020 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) ...

2020-12-28 08:00 6631

Innovent Announces NMPA Granted New Indication Approvals for SULINNO® (Adalimumab Injection) for the Treatment of Pediatric Plaque Psoriasis and Non-infectious Uveitis

SAN FRANCISCO and SUZHOU, China, Dec. 23, 2020 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) ...

2020-12-23 12:30 7260

Innovent Announces Parsaclisib Treatment Results in High Rate of Rapid and Durable Responses in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas

SAN FRANCISCO and SUZHOU, China, Dec. 8, 2020 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent")...

2020-12-08 08:00 3006
12345 ... 7